Hematology

The FDA approved a once-daily, 2-drug oral regimen for adults with virologically suppressed HIV-1 to replace existing antiretroviral therapy.

The FDA approved a once-daily, 2-drug oral regimen for adults with virologically suppressed HIV-1 to replace existing antiretroviral therapy.

The FDA approved a once-daily, 2-drug oral regimen for adults with virologically suppressed HIV-1 to replace existing antiretroviral therapy.

The FDA approved a once-daily, 2-drug oral regimen for adults with virologically suppressed HIV-1 to replace existing antiretroviral therapy.

The FDA approved a once-daily, 2-drug oral regimen for adults with virologically suppressed HIV-1 to replace existing antiretroviral therapy.

The FDA approved a once-daily, 2-drug oral regimen for adults with virologically suppressed HIV-1 to replace existing antiretroviral therapy.

On March 25, the FDA has approved relacorilant (Lifyorli), in combination with nab-paclitaxel for adults with platinum-resistant ovarian and related gynecologic cancers who have received prior systemic...

On March 25, the FDA has approved relacorilant (Lifyorli), in combination with nab-paclitaxel for adults with platinum-resistant ovarian and related gynecologic cancers who have received prior systemic...

On March 25, the FDA has approved relacorilant (Lifyorli), in combination with nab-paclitaxel for adults with platinum-resistant ovarian and related gynecologic cancers who have received prior systemic...

On March 25, the FDA has approved relacorilant (Lifyorli), in combination with nab-paclitaxel for adults with platinum-resistant ovarian and related gynecologic cancers who have received prior systemic...